Ajit Mahadevan told The Economic Times of India that credit restrictions will see biotechs increasingly turn to India. This will help drive growth from its current $200m a year, to the $600m that KPMG predicted it would reach by 2010.
Related topics: Clinical Development
The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences Practice.
Ajit Mahadevan told The Economic Times of India that credit restrictions will see biotechs increasingly turn to India. This will help drive growth from its current $200m a year, to the $600m that KPMG predicted it would reach by 2010.
Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions